{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "17883958", "DateCompleted": {"Year": "2008", "Month": "11", "Day": "18"}, "DateRevised": {"Year": "2018", "Month": "12", "Day": "11"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": [], "Journal": {"ISSN": "1671-4083", "JournalIssue": {"Volume": "28", "Issue": "10", "PubDate": {"Year": "2007", "Month": "Oct"}}, "Title": "Acta pharmacologica Sinica", "ISOAbbreviation": "Acta Pharmacol Sin"}, "ArticleTitle": "Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.", "Pagination": {"StartPage": "1685", "EndPage": "1692", "MedlinePgn": "1685-92"}, "Abstract": {"AbstractText": ["To explore the potential interactions between yin zhi huang (YZH) and omeprazole, a substrate of CYP3A4 and CYP2C19.", "Eighteen healthy volunteers, including 6 CYP2C19*1/*1, 6 CYP2C19*1/*2 or *3 and 6 CYP2C19*2/*2 were enrolled in a 2-phase, randomized, crossover clinical trial. In each phase, the volunteers received either placebo or 10 mL YZH oral liquid, 3 times daily for 14 d. Then all the patients took a 20 mg omeprazole capsule orally. Blood samples were collected up to 12 h after omeprazole administration. Plasma concentrations of omeprazole and its metabolites were quantified by HPLC with UV detection.", "After 14 d of treatment of YZH, plasma omeprazole significantly decreased and those of omeprazole sulfone and 5-hydroxyomeprazole significantly increased. The ratios of the area under the plasma concentration-time curves from time 0 to infinity (AUC(0-infinity) of omeprazole to 5-hydroxyomprazole and those of omeprazole to omeprazole sulfone decreased by 64.80%+/-12.51% (P=0.001) and 63.31%+/-18.45% (P=0.004) in CYP2C19*1/*1, 57.98%+/-14.80% (P=0.002) and 54.87%+/-18.42% (P=0.003) in CYP2C19*1/*2 or *3, and 37.74%+/-16.07% (P=0.004) and 45.16%+/-15.54% (P=0.003) in CYP2C19*2/*2, respectively. The decrease of the AUC(0-infinity) ratio of omeprazole to 5-hydroxyomprazole in CYP2C19*1/*1 and CYP2C19*1/*2 or *3 was greater than those in CYP2C19*2/*2 (P=0.047 and P=0.009).", "YZH induces both CYP3A4-catalyzed sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole leading to decreases in plasma omeprazole concentrations."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Hu-nan 410078, China."}], "Identifier": [], "LastName": "Fan", "ForeName": "Lan", "Initials": "L"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Wang", "ForeName": "Guo", "Initials": "G"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Wang", "ForeName": "Lian-Sheng", "Initials": "LS"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Chen", "ForeName": "Yao", "Initials": "Y"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhang", "ForeName": "Wei", "Initials": "W"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Huang", "ForeName": "Yuan-Fei", "Initials": "YF"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Huang", "ForeName": "Rui-Xue", "Initials": "RX"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Hu", "ForeName": "Dong-Li", "Initials": "DL"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Wang", "ForeName": "Dan", "Initials": "D"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhou", "ForeName": "Hong-Hao", "Initials": "HH"}], "PublicationTypeList": ["Journal Article", "Randomized Controlled Trial", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Acta Pharmacol Sin", "NlmUniqueID": "100956087", "ISSNLinking": "1671-4083"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "2-Pyridinylmethylsulfinylbenzimidazoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Ulcer Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Drug Combinations"}, {"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}, {"RegistryNumber": "0", "NameOfSubstance": "yin zhi huang"}, {"RegistryNumber": "76X040Z74O", "NameOfSubstance": "omeprazole sulfone"}, {"RegistryNumber": "92340-57-3", "NameOfSubstance": "5-hydroxymethylomeprazole"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Aryl Hydrocarbon Hydroxylases"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "CYP2C19 protein, human"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Cytochrome P-450 CYP2C19"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Cytochrome P-450 CYP3A"}, {"RegistryNumber": "EC 1.14.14.55", "NameOfSubstance": "CYP3A4 protein, human"}, {"RegistryNumber": "KG60484QX9", "NameOfSubstance": "Omeprazole"}, {"RegistryNumber": "RSB34337V9", "NameOfSubstance": "Safrole"}, {"RegistryNumber": "WOR3CS513R", "NameOfSubstance": "sulfoxide"}], "MeshHeadingList": [{"QualifierName": ["blood"], "DescriptorName": "2-Pyridinylmethylsulfinylbenzimidazoles"}, {"QualifierName": [], "DescriptorName": "Adult"}, {"QualifierName": ["blood", "metabolism", "pharmacokinetics"], "DescriptorName": "Anti-Ulcer Agents"}, {"QualifierName": [], "DescriptorName": "Area Under Curve"}, {"QualifierName": ["chemistry"], "DescriptorName": "Artemisia"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Aryl Hydrocarbon Hydroxylases"}, {"QualifierName": [], "DescriptorName": "Cross-Over Studies"}, {"QualifierName": [], "DescriptorName": "Cytochrome P-450 CYP2C19"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Cytochrome P-450 CYP3A"}, {"QualifierName": [], "DescriptorName": "Drug Combinations"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": [], "DescriptorName": "Genotype"}, {"QualifierName": [], "DescriptorName": "Herb-Drug Interactions"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects"], "DescriptorName": "Hydroxylation"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["analogs & derivatives", "blood", "metabolism", "pharmacokinetics"], "DescriptorName": "Omeprazole"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["analogs & derivatives", "metabolism"], "DescriptorName": "Safrole"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2007", "Month": "9", "Day": "22", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "11", "Day": "19", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "9", "Day": "22", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["17883958", "10.1111/j.1745-7254.2007.00617.x"]}}], "PubmedBookArticle": []}